A detailed history of D. E. Shaw & Co., Inc. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,128,577 shares of ZNTL stock, worth $3.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,128,577
Holding current value
$3.79 Million
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.9 - $4.57 $2.58 Million - $4.06 Million
888,236 Added 369.57%
1,128,577 $4.14 Million
Q2 2024

Aug 14, 2024

BUY
$4.09 - $16.13 $924,544 - $3.65 Million
226,050 Added 1581.76%
240,341 $982,000
Q1 2024

May 15, 2024

BUY
$10.83 - $16.49 $154,771 - $235,658
14,291 New
14,291 $225,000
Q3 2023

Nov 14, 2023

BUY
$19.63 - $28.29 $734,927 - $1.06 Million
37,439 New
37,439 $751,000
Q3 2022

Nov 14, 2022

SELL
$20.23 - $31.73 $518,555 - $813,335
-25,633 Reduced 46.82%
29,112 $631,000
Q2 2022

Aug 15, 2022

BUY
$17.91 - $52.25 $605,107 - $1.77 Million
33,786 Added 161.2%
54,745 $1.54 Million
Q1 2022

May 16, 2022

BUY
$41.58 - $80.89 $119,209 - $231,911
2,867 Added 15.85%
20,959 $967,000
Q4 2021

Feb 14, 2022

SELL
$66.92 - $84.79 $2.43 Million - $3.08 Million
-36,346 Reduced 66.77%
18,092 $1.52 Million
Q3 2021

Nov 15, 2021

SELL
$46.83 - $73.5 $94,409 - $148,176
-2,016 Reduced 3.57%
54,438 $3.63 Million
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $1.28 Million - $2.13 Million
34,283 Added 154.63%
56,454 $3 Million
Q1 2021

May 17, 2021

SELL
$35.69 - $52.72 $825,010 - $1.22 Million
-23,116 Reduced 51.04%
22,171 $962,000
Q4 2020

Feb 16, 2021

BUY
$31.71 - $57.97 $1.18 Million - $2.16 Million
37,294 Added 466.58%
45,287 $2.35 Million
Q3 2020

Nov 16, 2020

SELL
$27.03 - $47.97 $457,942 - $812,707
-16,942 Reduced 67.94%
7,993 $261,000
Q2 2020

Aug 14, 2020

BUY
$23.2 - $54.8 $578,492 - $1.37 Million
24,935 New
24,935 $1.2 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $191M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.